Sugi Predict

Sugi Predict / Compounds / SCHEMBL6798730

SCHEMBL6798730

SCHEMBL6798730

CC(C)(C)OC(=O)NCC12CCC(C(=O)O)(CC1)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ HCRTR2 O43614 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ CTSS P25774 3/20 0.36
▸ CTSK P43235 3/20 0.36
▸ CA12 O43570 2/20 0.36
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA9 Q16790 2/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ DGAT1 O75907 1/20 0.36
▸ SYK P43405 1/20 0.36
▸ NPFFR1 Q9GZQ6 1/20 0.35
▸ NPFFR2 Q9Y5X5 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27343894 1.00 MEN1 (0.41) MEN1KMT2AGAAHCRTR2TDP1
SCHEMBL29318799 0.87 HCRTR2 (0.40) MEN1KMT2AGAAHCRTR2TDP1
SCHEMBL10163707 0.87 HCRTR2 (0.40) MEN1KMT2AGAAHCRTR2TDP1
SCHEMBL8252987 0.86 MAOA (0.40) MEN1KMT2AGAAHCRTR2TDP1
SCHEMBL29317969 0.86 MAOA (0.40) MEN1KMT2AGAAHCRTR2TDP1
SCHEMBL8182460 0.86 HCRTR2 (0.39) MEN1KMT2AGAAHCRTR2TDP1
SCHEMBL31432022 0.85 HCRTR2 (0.41) MEN1KMT2AGAAHCRTR2TDP1
SCHEMBL26688348 0.85 MEN1 (0.41) MEN1KMT2AGAAHCRTR2TDP1
SCHEMBL27343898 0.85 HCRTR2 (0.41) MEN1KMT2AGAAHCRTR2TDP1
SCHEMBL8254109 0.84 HCRTR2 (0.39) MEN1KMT2AGAAHCRTR2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634169-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF Pfizer Inc. (US) 2025-10-22 — — EP disclosed
EP-4598908-A1 HSD17B13 INHIBITORS AND/OR DEGRADERS Pfizer Inc. (US) 2025-08-13 — — EP disclosed
CN-120202191-A Inhibitors of prostate specific membrane antigen and uses thereof 上海先通生物科技有限公司 2025-06-24 — — CN disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 — — US disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 — — US disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 — — US disclosed
WO-2024127297-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF PFIZER INC. (US) 2024-06-20 — — WO disclosed
WO-2024127297-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF PFIZER INC. (US) 2024-06-20 — — WO disclosed
US-20240150334-A1 HSD17B13 INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2024-05-09 — — US disclosed
WO-2024075051-A1 HSD17B13 INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2024-04-11 — — WO disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
WO-2006128184-A2 PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS ALANTOS-PHARMACEUTICALS, INC. (US) 2006-11-30 — — WO disclosed
US-20040058857-A1 Method of treating cancer YAO SIU-LONG (US) 2004-03-25 — — US disclosed
EP-1009420-B1 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER MERCK & CO INC (US) 2003-12-17 — — EP disclosed
US-20030220241-A1 Method of treating cancer DEFEO-JONES DEBORAH (US) 2003-11-27 — — US disclosed
US-20030215456-A1 Method of treating cancer YAO SUI-LONG (US) 2003-11-20 — — US disclosed
US-20020173451-A1 Method of treating cancer YAO SUI-LONG (US) 2002-11-21 — — US disclosed
US-20020041880-A1 Method of treating cancer DEFEO-JONES DEBORAH (US) 2002-04-11 — — US disclosed
US-20020042375-A1 Method of treating cancer HEIMBROOK DAVID C (US) 2002-04-11 — — US disclosed
US-6127333-A COMPRISING OLIGOPEPTIDES, HAVING AMINO ACID SEQUENCES THAT ARE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN AND KNOWN CYTOTOXIC AGENTS, CHARACTERIZED BY A DIAMINE LINKER BETWEEN THE OLIGOPEPTIDE AND VINBLASTINE MERCK & CO., INC. (US) 2000-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220241-A1 Method of treating cancer ACP3, PSAT1, LCAT MEN1 783/4885KMT2A 1240/4885GAA 615/4885
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders HSD17B13, HSD17B3, HSD17B1 MEN1 4182/4885KMT2A 1081/4885GAA 355/4885
US-20020042375-A1 Method of treating cancer ACP3, KLK3, FOLH1 MEN1 707/4885KMT2A 2337/4885GAA 853/4885
US-20040058857-A1 Method of treating cancer KLK3, SHBG, ACP3 MEN1 276/4885KMT2A 1984/4885GAA 496/4885
US-20240150334-A1 HSD17B13 INHIBITORS AND/OR DEGRADERS HSD17B1, HSD17B3, HSD17B13 MEN1 3752/4885KMT2A 2873/4885GAA 413/4885
US-20030215456-A1 Method of treating cancer TACR1, TACR2, KLK3 MEN1 521/4885KMT2A 995/4885GAA 1856/4885
US-20020173451-A1 Method of treating cancer FOLH1, KLK3, ACP3 MEN1 993/4885KMT2A 1907/4885GAA 214/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MEN1 3090/4885KMT2A 3548/4885GAA 352/4885
US-20020041880-A1 Method of treating cancer ACP3, FOLH1, KLK3 MEN1 859/4885KMT2A 1771/4885GAA 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.